CertiChem offers MDA-kb2 assays to assess the androgenic and anti-androgenic activities for chemicals and chemical mixtures. MDA-kb2 cells were developed by Drí Wilson et al. in EPA (Wilson, 2002). MDA-kb2 agonist assay is a luciferase reporter gene assay that has an increased amount of luciferase upon the binding of AR agonists to AR and reduce the agonist reference agonist (e.g., R1881 or DHT)-induced luciferase expression upon the binding of AR antagonists to AR. Both MDA-kb2 agonist and antagonist are currently under the validation by ICCVAM in CCi facility. Our BG1Luc assays are customized to meet the specific needs of our clients.
The advantages of our in vitro MDA-kb2 assays for detecting androgenic and anti-androgenic activities include:
(1) High accuracy, sensitivity and specificity.
(2) Ability to analyze mixtures of known or unknown chemicals.
(3) Low cost.
(4) Ability to analyze small amounts of suspect chemicals or chemical mixtures.
(5) In vitro assays can reduce animal use in compliance with protocols of the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM).
For information on pricing and certification, please contact us directly at email@example.com